Previous 10 | Next 10 |
MEI Pharma (NASDAQ: MEIP ) has risen another 16.7% postmarket after citing updated clinical data from an early-stage trial. More news on: MEI Pharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced updated data from the ongoing Phase 1b study of investigational ME-401, a selective oral inhibitor ...
SAN DIEGO , Sept. 23, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst event on Friday, October 4, 2019 from 8:00 a.m. ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 120 weeks of public selections as part of this ongoing live forward-testing. In...
SAN DIEGO , Aug. 29, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., president and chief executive officer, will present at the 2019 Wells Far...
MEI Pharma, Inc. (MEIP) Q4 2019 Earnings Conference Call August 28, 2019, 05:00 PM ET Company Participants David Walsey - VP, IR and Corporate Communications Brian Drazba - CFO Daniel Gold - President and CEO David Urso - COO, SVP, Corporate Development and General Counsel Ri...
MEI Pharma (NASDAQ: MEIP ): FY GAAP EPS of -$0.75 misses by $0.14 . More news on: MEI Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , Aug. 28, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2019 . "It was a very productive year, with each of the four clin...
SAN DIEGO , Aug. 21, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2019 fiscal year end financial results after the close of the U.S. financial...
We have posted our brief quarterly letter. Speed Read: Our underperformance this year reflects irrational prices that have become even less rational, particularly with the view we have on the board of our largest position; Our portfolio has higher FCF growth (+61% in the last 18 mont...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
16.08%Change Percent:
MEI Pharma Inc. Company Name:
MEIP Stock Symbol:
NASDAQ Market:
MEI Pharma Inc. Website:
Company Commences a Cash Preservation Plan Including a Reduction in Force MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including ...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...